Synonyms: compound 19 [WO2023018643A1]
Compound class:
Synthetic organic
Comment: The chemical structure for fosizensertib was derived from WHO proposed INN list 132 (Feb 2025), in which it is listed as a receptor-interacting serine/threonine protein kinase 1 (RIPK1) inhibitor. This generated a SMILES match via PubChem to a compound (19) claimed in patent WO2023018643A1 (AbbVie) [1]. This appears to be a phosphate prodrug, that is dephosphorylated in vivo, to the active metabolite compound 2. In the absence of formal structure disclosure (March 2025) we hypothesise that this is likely to be the INN for AbbVie's oral ulcerative colitis lead ABBV-668.
|
|
Immunopharmacology Comments |
RIPK1 is a key regulator of inflammation. It is involved in the induction of necroptosis, apoptosis, and pro-inflammatory cytokine production. Selective RIPK1 inhibitors offer therapeutic potential for the treatment of chronic autoimmune/inflammatory diseases. |